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Background: During the initial phases of the COVID-19 pandemic, there was an unfounded fervor surrounding the use of
hydroxychloroquine (HCQ) and tocilizumab (TCZ); however, evidence on their efficacy and safety have been controversial.
Objective: The purpose of this study is to evaluate the overall clinical effectiveness of HCQ and TCZ in patients with COVID-19.
We hypothesize that HCQ and TCZ use in these patients will be associated with a reduction in in-hospital mortality, upgrade to
intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis.
Methods: A retrospective cohort study was performed to determine the impact of HCQ and TCZ use on hard clinical outcomes
during hospitalization. A total of 176 hospitalized patients with a confirmed COVID-19 diagnosis was included. Patients were
divided into two comparison groups: (1) HCQ (n=144) vs no-HCQ (n=32) and (2) TCZ (n=32) vs no-TCZ (n=144). The mean
age, baseline comorbidities, and other medications used during hospitalization were uniformly distributed among all the groups.
Independent t tests and multivariate logistic regression analysis were performed to calculate mean differences and adjusted odds
ratios with 95% CIs, respectively.
Results: The unadjusted odds ratio for patients upgraded to a higher level of care (ie, intensive care unit) (OR 2.6, 95% CI
1.19-5.69; P=.003) and reductions in C-reactive protein (CRP) level on day 7 of hospitalization (21% vs 56%, OR 0.21, 95% CI
0.08-0.55; P=.002) were significantly higher in the TCZ group compared to the control group. There was no significant difference
in the odds of in-hospital mortality, upgrade to intensive medical care, need for invasive mechanical ventilation, acute kidney
failure necessitating dialysis, or discharge from the hospital after recovery in both the HCQ and TCZ groups compared to their
respective control groups. Adjusted odds ratios controlled for baseline comorbidities and medications closely followed the
unadjusted estimates.
Conclusions: In this cohort of patients with COVID-19, neither HCQ nor TCZ offered a significant reduction in in-hospital
mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. These results
are similar to the recently published preliminary results of the HCQ arm of the Recovery trial, which showed no clinical benefit
from the use of HCQ in hospitalized patients with COVID-19 (the TCZ arm is ongoing). Double-blinded randomized controlled
trials are needed to further evaluate the impact of these drugs in larger patient samples so that data-driven guidelines can be
deduced to combat this global pandemic.
(J Med Internet Res 2020;22(9):e21758) doi: 10.2196/21758
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As of July 23, 2020, more than 4 million cases and 140,000
deaths from COVID-19 have been reported in the United States.
There is currently no proven medical therapy for this disease
except low-dose dexamethasone and remdesivir based on
preliminary evidence with the mainstay of treatment being
supportive care [1]. Multiple off-label and compassionate use
therapies are currently being employed, targeting currently
known pathophysiological mechanisms of this novel virus.
Increasing social and economic devastation caused by
COVID-19 has led the Federal Drug Administration (FDA) to
issue emergency use authorizations (EUAs) for various drugs
without proven benefits [2]. Although many of these drugs have
revealed promising in vitro activity against the coronaviridae
family, including SARS-CoV-2, the translation of these in vitro
effects into clinical efficacy is a matter of debate. While, as
physicians, we tend to assume that these drugs will do more
good than harm when utilizing them as a last resort to severely
ill patients, the fact remains that in the absence of randomized
controlled trials, there is no way to reliably judge the impact of
these medications. Fortunately, this situation is being remedied,
with evidence emerging, initially from China, and more recently
from trials in the United States and Europe.
Among others, hydroxychloroquine (HCQ) and the interleukin-6
(IL-6) inhibitor, tocilizumab (TCZ), became popular options to
treat COVID-19. There is no concrete evidence supporting their
use, and they were widely adopted across the world based on
anecdotal data. Our hospital, following the guidelines of its
parent enterprise, permitted the use of HCQ in COVID-19
patients who had respiratory insufficiency as indicated by low
oxygen saturation. Similarly, TCZ was used for patients who
met the criteria for cytokine release syndrome during the time
frame of this study. The purpose of this study is to evaluate the
overall clinical effectiveness of HCQ and TCZ in our hospital.
We will compare our results to the preliminary results of the
HCQ arm of the RECOVERY trial, which did not reveal a
difference in 28-day mortality between the HCQ group and the
usual care group [3]. In addition to mortality, we will evaluate
other secondary endpoints and hypothesize that use of HCQ
and TCZ will be associated with a reduction in the endpoints
of an upgrade to the intensive care unit (ICU), need for invasive
mechanical ventilation (IMV), acute renal failure necessitating
dialysis, and reduction in D-dimer and C-reactive protein (CRP)
on the 7th day of hospitalization.
Methods
Study Design and Participants
This retrospective cohort study included adult inpatients (≥18
years old) from Abington Hospital - Jefferson Health in the
United States. All patients had a confirmed diagnosis of
COVID-19 between March 1, 2020, and May 30, 2020. The
study was approved by the Institutional Review Board, and the
requirement for informed consent was waived by the Research
Ethics Committee.
Data Collection
All COVID-19 patients who were admitted to the hospital
between March 1, 2020, and May 30, 2020, were included. Data
were extracted from electronic medical records (Sunrise) using
a standardized data collection form. All authors contributed to
data retrieval and an independent author adjudicated any
difference in interpretation between the data extractors.
SARS-CoV-2 was detected in respiratory specimens
(nasopharyngeal or throat swabs) by real-time qualitative
polymerase chain reaction (RT-qPCR). Routine blood work
included complete blood count, serum electrolytes, renal
function test, coagulation profile, serum ferritin, CRP, D-dimer
level, lactate dehydrogenase, and myocardial enzymes (troponin
T) on presentation to the hospital and on day 7 of hospitalization.
Baseline comorbidities, including hypertension (HTN), diabetes
mellitus (DM), chronic kidney disease (CKD), chronic
obstructive lung disease (COPD), and coronary artery disease
(CAD), were also recorded. The criteria of discharge from the
hospital after recovery included resolution of fever, absence of
symptoms for at least 1 day, and substantial clinical or
radiological improvement.
Statistical Analysis
A chi-square (χ2) test was used for comparison of categorical
data and Fisher exact test was adopted if the expected count in
more than 20% cells was less than 5. Continuous variables were
presented as means and standard deviations while categorical
variables were reported in percentages and proportions. To
quantify the association between the dichotomous categorical
variables, an unadjusted odds ratio (uOR) was obtained using
a Cochran-Mantel-Haenszel method. To explore the risk factors
and gauge the impact of potential effect modifiers (covariates)
on our endpoints (in-hospital mortality, ICU upgrade, IMV,
dialysis, and inflammatory marker level), binomial and
multinomial logistic regression models were applied. The
differences in the baseline comorbidities (DM, HTN, CAD,
CKD, and COPD) and medication use (HCQ, TCZ, remdesivir,
therapeutic anticoagulation, and steroids) were accounted for
to obtain an adjusted odds ratio (aOR) for all outcomes. For
normally and abnormally distributed continuous data, an
independent sample t test and Mann-Whitney U test were used,
respectively. A one-way analysis of variance (ANOVA) was
used to compare differences in the mean of continuous variables
for multiple in-hospital complications. A two-sided α<.05 was
considered statistically significant with corroborating inference
from a 95% CI. Statistical analyses were performed using the
SPSS software (version 25, IBM Corp).
Results
Demographics and Baseline Characteristics
Our study population consisted of 176 patients who were
hospitalized and had a confirmed case of COVID-19 infection.
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All patients were divided into two comparison groups: (1) HCQ
(n=144) vs no-HCQ (n=32) and (2) TCZ (n=32) vs no-TCZ
(n=144), respectively. Table 1 and Figure 1 depict the underlying
comorbidities and other medications used during hospitalization
in both comparison groups. The mean age in years for the HCQ
and no-HCQ groups was 63.75 and 65.87 years, respectively
(P=.55); for the TCZ and no-TCZ groups, it was 58.09 and
65.48 years, respectively (P=2.75). The most common
underlying comorbidities in all the four groups were DM, HTN,
CAD, CKD, and COPD. Common medications used during
hospitalization included steroids, anticoagulants, HCQ, and
TCZ. These underlying comorbidities and medications used
during hospitalization were nonsignificantly different between
the comparison groups (P≥.05). The detailed percentages of
group-wise comorbidities and demographics are given in Table
1.




60 (72.30)23 (27.70)16 (19.50)66 (80.50)Male, n (%)
74 (85.10)13 (14.90)10 (11.80)75 (88.20)Female, n (%)
.97.72Diabetes mellitus
86 (78.90)23 (21.10)16 (14.80)92 (85.20)No, n (%)
48 (78.70)13 (21.30)10 (16.90)49 (83.10)Yes, n (%)
.61.24Hypertension
46 (76.70)14 (23.30)12 (20.00)48 (80.00)No, n (%)
88 (80.00)22 (20.00)14 (13.10)93 (86.90)Yes, n (%)
.78.16Coronary artery disease
109 (78.40)30 (21.60)24 (17.40)114 (82.60)No, n (%)
25 (80.60)6 (19.40)2 (6.90)27 (93.10)Yes, n (%)
.56.65Chronic kidney disease
110 (79.70)28 (20.30)22 (16.20)114 (83.80)No, n (%)
24 (75.00)8 (25.00)4 (12.90)27 (87.10)Yes, n (%)
.56.29Chronic obstructive pulmonary disease
114 (78.10)32 (21.90)24 (16.80)119 (83.20)No, n (%)
20 (83.30)4 (16.70)2 (8.30)22 (91.70)Yes, n (%)
.25.39Steroids
108 (77.10)32 (22.90)23 (16.70)115 (83.30)No, n (%)
26 (86.70)4 (13.30)3 (10.30)26 (89.70)Yes, n (%)
.08.32Anticoagulation
111 (81.60)25 (18.40)19 (14.20)115 (85.80)No, n (%)
23 (67.60)11 (32.40)7 (21.20)26 (78.80)Yes, n (%)
aHCQ: hydroxychloroquine.
bTCZ: tocilizumab.
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Figure 1. Baseline comorbidities and medication use in the hydroxychloroquine (HCQ) group, tocilizumab (TCZ) group, and control groups. The
x-axis represents sex, comorbidities, medications, C-reactive protein (CRP), and D-dimer level at presentation; the y-axis represents the percentage of
subjects. DM: diabetes mellitus; HTN: hypertension; CKD: chronic kidney disease; CAD: coronary artery disease; COPD: chronic obstructive pulmonary
disease; AC: anticoagulation.
Odds Ratios of Outcomes
Table 2 and Figures 2 and 3 compare the above-mentioned
outcomes between the TCZ group and the no-TCZ group. The
unadjusted odds ratio for patients requiring an upgrade to the
ICU was significantly higher in those who received TCZ
compared to the control group (OR 2.6, 95% CI 1.19-5.69;
P=.003). Similarly, patients who received TCZ had a significant
reduction in CRP levels on day 7 of hospitalization compared
to the control group (21% vs 56%, OR 0.21, 95% CI 0.08-0.55;
P=.002). However, this reduction in the inflammatory markers
did not translate into clinical benefits. There was no significant
difference in the unadjusted odds of in-hospital mortality, IMV,
acute renal failure necessitating dialysis, and discharge from
the hospital after recovery between the two groups. The
proportion of high D-dimer levels (>500 ng/dL) and elevated
CRP (>100 ng/dL) on day 7 of hospitalization were also
identical between the TCZ and no-TCZ groups. However, when
we adjusted the observed odds ratios for baseline comorbidities,
including DM, HTN, CKD, CAD, COPD, medications, use of
anticoagulation at home, therapeutic anticoagulation during
hospital stay, as well as steroid and HCQ use in the TCZ
comparison group, the adjusted odds values were consistent
with unadjusted odds ratios for all the outcomes. The exception
was for an upgrade to medial ICU, where there was no
difference between the TCZ group and the no-TCZ group. This
is contrary to the unadjusted odds, which revealed more ICU
upgrades in the TCZ group compared to the no-TCZ group
(Table 2). The forest plots given in Figures 2 and 3 reveal the
difference in unadjusted and adjusted odds between the TCZ
group and the no-TCZ group.
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Table 2. Tocilizumab (TCZ) regression analysis with outcome.
P valueaORb (95% CI)P valueuORa (95% CI)No TCZ, nTCZ, nOutcome
.671.2 (0.49-2.9).141.94 (0.89-4.23)3147Invasive mechanical
ventilation
.141.9 (0.80-4.5).032.6 (1.19-5.69)2850Upgrade




.470.7 (0.31-1.7).990.93 (0.43-2.015250Day 1
.451.4 (0.52-4.2).241.92 (0.76-4.9)6477Day 7
C-reactive protein
.591.26 (0.54-2.93).551.38 (0.63-3.04)5563Day 1
.0010.17 (0.05-0.50).0020.21 (0.08-0.55)5621Day 7
auOR: unadjusted odds ratio.
baOR: adjusted odds ratio.
Figure 2. Forest plot comparing unadjusted odds of outcomes between the tocilizumab (TCZ) and no-TCZ groups. CRP: C-reactive protein.
J Med Internet Res 2020 | vol. 22 | iss. 9 | e21758 | p. 5https://www.jmir.org/2020/9/e21758
(page number not for citation purposes)
Roomi et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Figure 3. Forest plot comparing adjusted odds of outcomes between the tocilizumab (TCZ) and no-TCZ groups. CRP: C-reactive protein.
Similarly, Table 3 and Figures 4 and 5 compare the
above-mentioned outcomes between the HCQ group and the
no-HCQ group. The use of HCQ in patients with COVID-19
was not associated with a significant improvement in any of the
outcomes. The unadjusted odds ratio of in-hospital mortality,
upgrade to ICU, IMV, acute renal failure needing dialysis, or
discharge after recovery were identical between patients
receiving HCQ or not, respectively. Similarly, the proportion
of high D-dimer and CRP levels on day 7 of hospitalization was
not significantly different between the HCQ and no-HCQ
groups. As with the TCZ comparison group, a multivariate
regression analysis was used to adjust the observed odds ratios
for baseline comorbidities and medications including TCZ in
the HCQ comparison group. The adjusted odds values were
consistent with unadjusted odds ratios for all the outcomes as
having been depicted by similar forest plots in Figures 4 and 5.
Table 3. Hydroxychloroquine (HCQ) regression analysis with outcome.
P valueaORb (95% CI)P valueuORa (95% CI)No HCQ, nHCQ, nOutcome







.630.8 (0.3-1.9).950.89 (0.37-2.10)5451Day 1
.163.6 (0.59-22.7).184.47 (0.77-25)3369Day 7
C-reactive protein
.310.64 (0.27-1.51.620.75 (0.33-1.69)6255Day 1
.442.0 (0.33-12.8).502.42 (0.45-12.952949Day 7
auOR: unadjusted odds ratio.
baOR: adjusted odds ratio.
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Figure 4. Forest plot comparing unadjusted odds of outcomes between the hydroxychloroquine (HCQ) and no-HCQ groups. CRP: C-reactive protein.
Figure 5. Forest plot comparing the adjusted odds of outcomes between hydroxychloroquine (HCQ) and no-HCQ groups. CRP: C-reactive protein.
Discussion
Principal Findings
The purpose of this study is to evaluate the overall clinical
effectiveness of HCQ and TCZ in our hospital. Our results
revealed that both TCZ and HCQ had no role in improving hard
clinical outcomes in patients with COVID-19 admitted to the
hospital. Compared to patients in the control group, those who
received either of these medications did not show a significant
reduction in the rate of in-hospital mortality, upgrade to ICU,
IMV, reduction in acute renal failure to the point of needing
dialysis, or discharge from the hospital after recovery. Although
the patients who received TCZ appeared to have a higher rate
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of ICU upgrade, this trend seemed to be driven by multiple
comorbidities in the TCZ group, as evidenced by an identical
adjusted odds ratio on multivariate analysis (Table 2; Figures
2 and 3). Partly contributing to this might be the higher use of
TCZ in the sicker patients who fulfilled the criterion to receive
the drug based on disease severity.
HCQ and TCZ, the major therapy for rheumatological diseases,
have recently gained attention as one of the major cornerstone
management approaches for COVID-19. HCQ is thought to
work by inhibiting glycosylation of the host receptors,
endosomal acidification, and proteolytic processing thereby,
blocking viral entry into host cells [4-7]. TCZ, on the other hand
is believed to counteract the misdirected immune response
related to the COVID-19 cytokine storm [8]. Being a
monoclonal antibody directed against IL-6, TCZ is thought to
dampen the immune response and potentially reduce the adverse
outcomes related to COVID-19.
A previous study by Xu et al [9] has shown a significant
improvement in respiratory function (91% reduction in
symptoms) and length of hospital stay in COVID-19 patients
with a single dose of TCZ. However, that study was
underpowered (n=21 patients) and had no control arm [9].
Similarly, Luo and colleagues [10] observed an 80% survival
rate in patients receiving TCZ. Their study also was not followed
up by a large-scale study and had several limitations. A recently
published retrospective cohort study that included 544 patients
admitted in different hospitals of Italy revealed that after
adjustment for sex, age, recruiting center, duration of symptoms,
and SOFA (sequential organ failure assessment) score, TCZ
treatment was associated with a reduced risk of IMV or death
(adjusted hazard ratio 0.61, 95% CI 0.40-0.92; P=.020) [11].
Our study consisted of 176 patients, and it demonstrated that
there were no major clinical benefits to TCZ use in COVID-19
patients. A significant reduction of CRP levels on day 7 of
hospitalization was observed in the TCZ group compared to the
control group; yet this difference did not translate into clinical
benefits in terms of a reduction in in-hospital mortality, medical
ICU upgrade, or reduction in IMV (Figures 2 and 3). As
mentioned in the study limitations below, a larger patient
population and a randomized controlled design might have
demonstrated a clinical benefit parallel to this reduction in CRP
level. Among other ongoing randomized, double-blinded,
controlled trials, the Oxford-based RECOVERY trial is also
recruiting participants who meet the eligibility criteria into the
TCZ arm of the trial [12].
Similarly, preliminary data from China reported that HCQ use
was associated with a reduction in the viral load, duration of
disease, and resolution of COVID-19 pneumonitis on imaging
[13]. A small, nonrandomized, open-label French study
consisting of 36 patients also reported significant reduction in
the viral load in patients taking HCQ [14]. Major subsequent
large-scale trials also reported its potential utility in reducing
the need for IMV. However, the medical community was
concerned regarding the potential cardiovascular adverse effects
of off-label HCQ use. Despite all the controversies surrounding
HCQ, its use prevailed in the earlier part of the pandemic,
leading to stockpiling and shortage of HCQ in international
markets, then followed by a swift decline in its use [15].
In our study, we systematically determined the impact of HCQ
on the hard clinical outcomes in the COVID-19 cohort. Our
mortality analysis showed a nonsignificant difference in the
rate of in-hospital mortality in patients receiving HCQ group
compared to those in the control group. It should be noted,
however, that there was a two-fold higher risk of death in the
HCQ arm. These findings are in line with a previous study by
Magagnoli et al [16] that also reported a three times higher odds
of death in patients receiving HCQ. Following this, another
French study consisting of 181 patients with diagnosed
COVID-19 pneumonitis reported that HCQ use was of no benefit
[17]. In terms of mortality, the results of our study are similar
to the recently published preliminary results of the RECOVERY
trial in which patients were randomized between the HCQ group
(n=1542) and usual care group (n=3132). There was no
significant difference in 28-day mortality between the two
groups (hazard ratio 1.11, 95 % CI 0.98-1.26; P=.10) [3].
Following these results, the FDA revoked the EUA for use of
HCQ in COVID-19 patients on June 15, 2020 [18].
The most debilitating complication of SARS-CoV-2 infection
is acute respiratory failure, necessitating the use of IMV and
other concurrent resource-intensive tools in critical care units
[15]. Previous studies have reported mixed results, showing
11% to 44% use of IMV in patients receiving HCQ and TCZ
[13,19,20]. Magagnoli et al [17] included sicker patients, who
were more likely to receive HCQ on compassionate grounds
and hence were more prone to have adverse outcomes and death,
calling into question its reliability. By contrast, our analysis
adjusted the pooled estimate of IMV requirement in both HCQ
and TCZ groups by identifying major potential confounders
such as baseline comorbidities and other medications used
during the hospital stay. By demonstrating a nonsignificant
trend in all the above-mentioned outcomes, we recommend
against the routine use of HCQ and TCZ in patients with
COVID-19.
Limitations
The limitations of our study should be considered when
interpreting the results. Due to the retrospective nonrandomized
nature of the study, a causal relationship could not be
established. Although the overall findings were adjusted for
covariates including baseline comorbidities and medications,
the impact of unmeasured confounders, such as initiation of
several complementary therapies at the treating physician’s
discretion, could not be determined. Based on our clinical
experience, the average duration of any therapy for COVID-19
was less than 7 days; therefore, we chose to use laboratory
values from day 1 and day 7. However, given the variable
frequency of laboratory specimen collection, it is not possible
for us to ascertain if these values truly represented pre- and
posttreatment values accurately in all cases. The patients who
received TCZ were mainly selected based on the availability of
the drug (which was in short supply intermittently during the
time frame of our study), and these patients were sicker with
lower PaO2/FiO2 ratios. Moreover, by excluding patients still
in the hospital, the case fatality ratio in our study cannot reflect
the true mortality of COVID-19. Our study did show a trend of
beneficial events in terms of the point estimate of the pooled
effect size. However, there was an overlap in the confidence
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intervals and broad confidence intervals indicating that our
study was underpowered to reach the level of significance.
Although we adjusted the outcomes against demographics and
underlying comorbidities, neither did we evaluate the
contribution of underlying comorbidities to COVID-19 mortality
via propensity score matching nor did our study evaluate the
potentially harmful effects of these medications. We believe
that a large-scale study will determine the true merits of these
medications and will also reveal the potentially harmful
outcomes of these medications. Many questions remain open,
however. By adjusting the adult patients with the confirmed
disease, we believe our population is the representative of the
real-world cohort.
Conclusion
HCQ and TCZ use was not associated with a reduction in
endpoints of in-hospital mortality, upgrade to medical ICU,
need for IMV, acute renal failure necessitating dialysis, or
discharge from the hospital. Although there was a significant
reduction in CRP level on day 7 of hospitalization in the patients
receiving TCZ, the lack of improvement in hard clinical
outcomes suggests that large-scale randomized controlled trials
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